Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings

Annals of Oncology

Volumn 24, Issue 11, 2013, Pages 2801-2807

  Abdel Fatah, T M A ^a   Perry, C ^a,b   Dickinson, P ^a   Ball, G ^c   Moseley, P ^a   Madhusudan, S ^a,b   Ellis, I O ^b   Chan, S Y T ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIGEN; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIRUBICIN; FLUOROURACIL; P CADHERIN; PROTEIN BCL 2; PROTEIN MDMX; PROTEIN P27; SPERM ASSOCIATED ANTIGEN 5; UNCLASSIFIED DRUG; UVOMORULIN;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

ANTHRACYCLIN CHEMOTHERAPY; BCL2; PREDICTIVE MARKER; PROGNOSTIC MARKER; THERAPUTIC TARGETS; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84887098542     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt277     Document Type: Article

References (17)

1. WHO Globocan 2008: Estimated cancer incidence, mortality, prevalence and disability-adjusted life years (DALYs) worldwide in 2008 2nd January 2013]; Available from: http://globocan.iarc.fr/ (22 February 2013, date last accessed)
2. V. Ossovskaya Y. Wang A. Budoff Exploring molecular pathways of triple-negative breast cancer Genes Cancer 2 2011 870 879
3. O. Brouckaert H. Wildiers G. Floris Update on triple-negative breast cancer: prognosis and management strategies Int J Womens Health 4 2012 511 520
4. K.D. Amos B. Adamo C.K. Anders Triple-negative breast cancer: an update on neoadjuvant clinical trials Int J Breast Cancer 2012 2012 385978
5. C.M. Perou Molecular stratification of triple-negative breast cancers Oncologist 15 Suppl 5 2010 39 48
6. S. Barrans S. Crouch A. Smith Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab J Clin Oncol 28 2010 3360 3365
7. G. von Minckwitz H.P. Sinn G. Raab Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast Breast Cancer Res 10 2008 R30
8. G.M. Callagy P.D. Pharoah S.E. Pinder Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index Clin Cancer Res 12 2006 2468 2475
9. S.J. Dawson N. Makretsov F.M. Blows BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received Br J Cancer 103 2010 668 675
10. G. Gasparini M. Barbareschi C. Doglioni Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer Clin Cancer Res 1 1995 189 198
11. A. Sierra X. Castellsague A. Escobedo Bcl-2 with loss of apoptosis allows accumulation of genetic alterations: a pathway to metastatic progression in human breast cancer Int J Cancer 89 2000 142 147
12. J.C. Reed Bcl-2 and the regulation of programmed cell death J Cell Biol 124 1994 1 6
13. L.A. O'Reilly D.C. Huang A. Strasser The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry EMBO J 15 1996 6979 6990
14. H.J. van Slooten M.J. van de Vijver C.J. van de Velde Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity Br J Cancer 77 1998 789 796
15. T.M. Abdel-Fatah D.G. Powe G. Ball Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer J Pathol 222 2010 388 399
16. H.R. Ali S.J. Dawson F.M. Blows A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer J Pathol 226 2012 97 107
17. S. Paik S. Shak G. Tang A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2004 2817 2826